IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
Rhea-AI Summary
IGC Pharma (NYSE American: IGC) announced on January 22, 2026 that Integrative Clinical Trials, LLC in Brooklyn, New York, has joined its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.
The new site, led by Principal Investigator Dr. Inna Yuryev-Golger, MD, expands the trial's clinical footprint in a major metropolitan area and is expected to support patient enrollment and diversity given the site's CNS research experience. IGC-AD1 is being studied in a randomized, double-blind, placebo-controlled Phase 2 trial. The company said the site addition strengthens trial execution and data quality as CALMA advances.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IGC gained 7.31%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $29M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IGC was up 0.18% pre-news, while peers showed mixed moves: CASI +5.93%, KLTO
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Trial site expansion | Positive | -0.1% | Added Dominion Medical Associates as a CALMA Phase 2 trial site. |
| Jan 06 | Reporting change | Positive | -1.3% | Aligned fiscal year with calendar year to aid U.S. investor comparability. |
| Jan 05 | Capital raise | Negative | +0.6% | Registered direct offering to fund IGC-AD1 Phase 2 and general purposes. |
| Dec 19 | Patent grant | Positive | -10.7% | USPTO issued patent for microdose-based cannabinoid treatment for tics. |
| Dec 15 | Policy positioning | Positive | -3.9% | Outlined potential benefits from federal momentum toward Schedule III status. |
Recent news, including clinical and strategic updates, has often coincided with negative or muted next-day price reactions, even on seemingly positive developments.
Over the past few months, IGC issued several updates tied to its IGC-AD1 program and corporate positioning. Clinical-trial-related releases on Jan 12, 2026 and Jan 5, 2026 focused on CALMA trial expansion and financing, while other news highlighted a fiscal-year change, a new U.S. patent, and potential benefits from Schedule III cannabinoid reclassification. Despite generally constructive narratives, 24-hour price reactions after these events were frequently negative, underscoring a pattern of investor caution around news flow.
Regulatory & Risk Context
An effective resale shelf on Form S-3/A filed Dec 3, 2025 covers up to 978,235 shares, including 390,000 option shares, for existing holders. IGC does not receive proceeds from these resales but bears registration costs. The shelf has been used at least once, as indicated by a 424B5 filing on Jan 5, 2026.
Market Pulse Summary
The stock moved +7.3% in the session following this news. A strong positive reaction aligns with IGC’s pattern of using clinical updates to reinforce progress in the CALMA Phase 2 program, even as the stock trades 43.71% below its 52-week high and under its $0.34 200-day MA. Investors have recently absorbed a dilutive 779,997-share offering and an active resale shelf covering 978,235 shares, factors that could temper follow-through if enthusiasm fades.
Key Terms
central nervous system medical
cns medical
randomized, double-blind, placebo-controlled medical
cannabinoid-based medical
AI-generated analysis. Not financial advice.
- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study -
POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced the addition of Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site participating in the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease.
Integrative Clinical Trials is a clinical research center conducting studies across a broad range of Central Nervous System ("CNS") disorders, including Alzheimer's disease and mild cognitive impairment. The site is led by Dr. Inna Yuryev-Golger, MD, who serves as Principal Investigator and brings more than 10 years of experience conducting clinical research. Bella Yevseva serves as the Clinical Trial Coordinator.
"Adding Integrative Clinical Trials further strengthens our CALMA clinical network with a site that has deep expertise across CNS disorders," said Ram Mukunda, CEO of IGC Pharma. "Their experience in neuropsychiatric and neurodegenerative research supports our commitment to high-quality data generation and efficient trial execution as we advance IGC-AD1."
Located at 2409 Ocean Avenue, Unit 1F, Brooklyn, New York, Integrative Clinical Trials expands IGC Pharma's presence in a major metropolitan area with access to a diverse patient population. The Company believes that incorporating sites with broad CNS experience is important to supporting enrollment and patient engagement.
IGC-AD1 is an investigational cannabinoid-based investigational therapy being evaluated in a randomized, double-blind, placebo-controlled Phase 2 clinical trial for agitation in patients with Alzheimer's disease. The continued expansion of the CALMA trial's clinical footprint reflects IGC Pharma's strategy to support enrollment and maintain rigorous clinical oversight.
To learn more about the trial and participation, visit https://igcpharma.com/igc-ad1-phase-ii/.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information:
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What did IGC (IGC) announce on January 22, 2026 about the CALMA Phase 2 trial?
Who is the principal investigator at the new IGC CALMA site in Brooklyn?
How does the new Integrative Clinical Trials site affect IGC-AD1 enrollment for IGC's CALMA trial?
What type of study is IGC-AD1 being evaluated in for IGC's CALMA trial?
Where is the new Integrative Clinical Trials site located for IGC's CALMA study?
How can potential participants learn more about the IGC-AD1 Phase 2 CALMA trial (IGC)?
